SHEILANIE CASABAY: Open Payments
NPI 1235794173 · VISALIA, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$696 in 39 payments from 10 companies in 2025. Trend: 2023 $913 · 2024 $914 · 2025 $696
Food & beverage: $662Education: $34
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 16 | $172 |
| Regeneron Healthcare Solutions, Inc. | 9 | $164 |
| Amgen Inc. | 3 | $83 |
| GENZYME CORPORATION | 3 | $77 |
| ARS Pharmaceuticals Operations, Inc. | 2 | $56 |
| Novartis Pharmaceuticals Corporation | 2 | $54 |
| AstraZeneca Pharmaceuticals LP | 1 | $33 |
| Optinose US, Inc. | 1 | $21 |
| Galderma Laboratories, L.P. | 1 | $19 |
| Paratek Pharmaceuticals, Inc. | 1 | $18 |
Products named: DUPIXENT, NUCALA, TRELEGY ELLIPTA, NEFFY, TEZSPIRE, XHANCE, AIRSUPRA, Rhapsido.
Industry payments across CA — which companies pay providers there.
